Sunday, May 26, 2019
By Dr. Ashutosh Singh, Consultant Psychiatrist, Apollo Hospital, Indore
Swiss drugmaker Novartis has received US approval for its spinal muscular atrophy gene therapy Zolgensma – pricing the one-time treatment at a record $2.125m.
The Food and Drug Administration on Frid...
By Dr. Ashutosh Singh, Indore
The U.S. Food and Drug Administration today permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription-only device, called the Monarch external Trigeminal Nerve Stimulation (e...
FDA permits marketing of first medical device for treatment of ADHD
May 26, 2019
US FDA approves Zolgensma - world's most expensive drug, pricing one time treatment at $2.125m (₹14Cr)
May 2019 (2)